TW202305120A - 新穎方法 - Google Patents

新穎方法 Download PDF

Info

Publication number
TW202305120A
TW202305120A TW111113146A TW111113146A TW202305120A TW 202305120 A TW202305120 A TW 202305120A TW 111113146 A TW111113146 A TW 111113146A TW 111113146 A TW111113146 A TW 111113146A TW 202305120 A TW202305120 A TW 202305120A
Authority
TW
Taiwan
Prior art keywords
cells
composition
feeder
feeder cells
cell
Prior art date
Application number
TW111113146A
Other languages
English (en)
Chinese (zh)
Inventor
安德魯 約翰 赫頓
伊斯特凡 科瓦奇
奧利弗 努斯包默
Original Assignee
英商伽瑪德爾塔治療有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 英商伽瑪德爾塔治療有限公司 filed Critical 英商伽瑪德爾塔治療有限公司
Publication of TW202305120A publication Critical patent/TW202305120A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K40/4255—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
TW111113146A 2021-04-09 2022-04-07 新穎方法 TW202305120A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB2105113.1 2021-04-09
GBGB2105113.1A GB202105113D0 (en) 2021-04-09 2021-04-09 Novel method

Publications (1)

Publication Number Publication Date
TW202305120A true TW202305120A (zh) 2023-02-01

Family

ID=75949435

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111113146A TW202305120A (zh) 2021-04-09 2022-04-07 新穎方法

Country Status (15)

Country Link
US (1) US20240197875A1 (https=)
EP (1) EP4320225A1 (https=)
JP (1) JP2024515064A (https=)
KR (1) KR20230167047A (https=)
CN (1) CN117222732A (https=)
AR (1) AR125325A1 (https=)
AU (1) AU2022254859A1 (https=)
BR (1) BR112023020584A2 (https=)
CA (1) CA3216225A1 (https=)
CO (1) CO2023015121A2 (https=)
GB (1) GB202105113D0 (https=)
IL (1) IL307395A (https=)
MX (1) MX2023011975A (https=)
TW (1) TW202305120A (https=)
WO (1) WO2022214825A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121532496A (zh) * 2023-07-20 2026-02-13 武田药品工业株式会社 用于制备γδT细胞的无网格方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6028176A (en) 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
WO2007111714A2 (en) 2005-11-28 2007-10-04 Zymogenetics, Inc. Il-21 antagonists
CA2860170C (en) 2010-12-22 2022-06-14 The Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
RU2739770C2 (ru) 2014-06-11 2020-12-28 полибайосепт ГмбХ Экспансия лимфоцитов с использованием композиции цитокинов для активной клеточной иммунотерапии
IL297773B2 (en) * 2014-11-17 2024-07-01 Adicet Bio Inc Engineered gamma delta t-cells
WO2017072367A1 (en) 2015-10-30 2017-05-04 Cancer Research Technology Limited EXPANSION OF NON-HAEMATOPOIETIC TISSUE-RESIDENT γδ T CELLS AND USES OF THESE CELLS
KR20190098747A (ko) * 2016-12-05 2019-08-22 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 치료법을 위한 조작된 세포의 제조방법
GB201707048D0 (en) * 2017-05-03 2017-06-14 King S College London Expansion of gamma delta cells, compositions, and methods of use thereof
CA3106056A1 (en) * 2018-07-26 2020-01-30 Ospedale Pediatrico Bambino Gesu (Opbg) Therapeutic preparations of gamma-delta t cells and natural killer cells and methods for manufacture and use
CN113423820A (zh) 2018-11-08 2021-09-21 伽马三角洲疗法有限公司 分离和扩增细胞的方法
GB201818243D0 (en) 2018-11-08 2018-12-26 Gammadelta Therapeutics Ltd Methods for isolating and expanding cells

Also Published As

Publication number Publication date
CN117222732A (zh) 2023-12-12
CA3216225A1 (en) 2022-10-13
AU2022254859A1 (en) 2023-10-19
IL307395A (en) 2023-12-01
MX2023011975A (es) 2023-12-14
GB202105113D0 (en) 2021-05-26
AR125325A1 (es) 2023-07-05
KR20230167047A (ko) 2023-12-07
BR112023020584A2 (pt) 2023-12-05
JP2024515064A (ja) 2024-04-04
US20240197875A1 (en) 2024-06-20
CO2023015121A2 (es) 2024-01-25
EP4320225A1 (en) 2024-02-14
WO2022214825A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
JP7665513B2 (ja) 細胞を単離及び拡大する方法
AU2017277499B2 (en) Compositions and methods for treating cancer
KR101408565B1 (ko) Ｔ 세포 집단의 제조 방법
CN113766919B (zh) 制造抗bcma car t细胞
AU2019459423B2 (en) Anti-B7-H4 chimeric antigen receptor-modified NK-92 cells
AU2020242520B2 (en) Method for the expansion and differentiation of T lymphocytes and NK cells in adoptive transfer therapies
JP7706361B2 (ja) 細胞を単離及び拡大する方法
MXPA04009287A (es) Proceso para producir linfocito citotoxico.
EP1666589B1 (en) Process for producing cytotoxic lymphocytes
CN108495865A (zh) 具有细胞因子受体激活或阻断结构域的嵌合抗原受体
CN101580817A (zh) 含有细胞因子诱导杀伤细胞的细胞群的制造方法
KR20250018168A (ko) 막-결합된 il-15, cd8 폴리펩티드, 세포, 조성물, 및 이의 사용 방법
US20110086367A1 (en) Pharmaceuticals for influencing the reaction of the human immune system
CN113755529A (zh) 一种肿瘤增强型肿瘤浸润淋巴细胞的制备方法
KR102829749B1 (ko) 배양보조세포를 포함하는 자연살해세포 증식용 조성물
US20240197875A1 (en) Novel method
JP2023021361A (ja) メラノーマの処置のための方法および組成物
JP2002506980A (ja) 新規の相補的レセプター−リガンド対およびそれを使用する養子免疫療法
CN115667501A (zh) 用于分离γδT细胞的方法
WO2023276395A1 (ja) キメラサイトカイン受容体
HK40058178A (en) Method for the expansion and differentiation of t lymphocytes and nk cells in adoptive transfer therapies
CN119775432A (zh) 靶向cd56的嵌合信号感受器和用于表达该感受器的细胞
CN121568707A (zh) CAR-ThyTreg细胞、组合物及其在免疫疗法中的用途
CN121586727A (zh) 组成型细胞因子受体
MX2008004225A (es) Metodo para la produccion de una poblacion de celulas t